FAR EAST PHARMACEUTICAL TECHNOLOGY COMPANY LIMITED

CONSOLIDATED CASH FLOW STATEMENT

Year ended 30 June 2001

	Notes	2001 HK\$'000	2000 HK\$′000
NET CASH INFLOW FROM OPERATING ACTIVITIES	25(a)	118,532	96,238
RETURNS ON INVESTMENTS AND SERVICING OF FINANCE			
Interest received		2,459	210
Interest paid		(236)	(148)
Dividends paid		(15,000)	(51,401)
Net cash outflow from returns on investments and			
servicing of finance		(12,777)	(51,339)
ТАХ			
Overseas tax paid		(17,109)	(8,390)
INVESTING ACTIVITIES			
Purchases of fixed assets		(66,694)	(13,174)
Capital contribution to a jointly-controlled entity		(131)	—
Acquisition of a subsidiary	25(c)	(9,687)	—
Repayment from a related company			8,900
Net cash outflow from investing activities		(76,512)	(4,274)
NET CASH INFLOW BEFORE FINANCING ACTIVITIES		12,134	32,235
FINANCING ACTIVITIES	25(b)		
Repayment of bank loans		(17,514)	(2,327)
Proceeds from issue of shares for cash consideration		103,730	—
Share issue expenses		(13,952)	
Net cash inflow/(outflow) from financing activities		72,264	(2,327)
INCREASE IN CASH AND CASH EQUIVALENTS		84,398	29,908
Cash and cash equivalents at beginning of year		33,161	3,253
CASH AND CASH EQUIVALENTS AT END			
OF YEAR		117,559	33,161
ANALYSIS OF BALANCES OF CASH			
AND CASH EQUIVALENTS			
Cash and bank balances		117,559	33,161
			,

